Subscribe
Subscribe
MY AMERICAN SCIENTIST
LOG IN! REGISTER!
SEARCH
 
Logo IMG
HOME > MULTIMEDIA > Multimedia Detail

SCIENCE IN THE NEWS DAILY

Promising Alzheimer's Drug Approved for Late-Stage Trials

from USA Today

An experimental drug for Alzheimer's disease patients showed promise in Phase II clinical trials and is moving into final-stage trials, Wyeth and Elan, the makers of bapineuzumab, announced Tuesday.

Bapineuzumab is designed to fight beta amyloid, a toxic protein that clumps together in the brains of Alzheimer's patients.

In the early studies, conducted around the USA, 240 people with early- to moderate-stage Alzheimer's disease were either assigned bapineuzumab or a placebo. Researchers reported that non-carriers of a gene considered to be a risk factor for Alzheimer's disease, called ApoE4, showed "clinically meaningful benefits" in a battery of tests used to track the progression of Alzheimer's disease.

Read more ...


comments powered by Disqus
 

Connect With Us:

Facebook Icon Sm Twitter Icon Google+ Icon Pinterest Icon RSS Feed Instagram Icon

Latest Multimedia

Flooded Sign

PODCAST & VIDEO: Engineering Around Extreme Events

Extreme events, such as super floods and hurricanes, are becoming more common, so civil engineers are trying to adapt civil infrastructure such as bridges to these unpredictable and sometimes devastating meteorological events. Engineer Ana Barros discusses how engineering can prepare us for extreme weather events, but also how changing climate and population conditions can affect the ability of infrastructure to hold up over time.

To view all multimedia content, click "Latest Multimedia."



RSS Feed Subscription

Receive notification when new content is posted from the entire website, or choose from the customized feeds available.


EMAIL TO A FRIEND :

Of Possible Interest

Science In The News Daily: Three Doctors Charged in Armstrong Doping Case

Science In The News Daily: Fish Oil Fail: Omega-3s May Not Protect Brain Health After All

Science In The News Daily: Antibody Cocktail Cures Monkeys of Ebola

Subscribe to American Scientist